6;355:
549-59.

85. Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE,
Callahan A 3rd, et al. Effects of intense low-density lipoprotein
cholesterol reduction in patients with stroke or transient ischemic
attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2007;38:3198-204.
86. Collins R, Armitage J, Parish S, Sleight P, Peto R. Effects of
cholesterol-lowering with simvastatin on stroke and other major
vascular events in 20536 people with cerebrovascular disease or
other high-risk conditions. Lancet 2004;363:757-67.
87. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey
Smith G, et al. Statins for the primary prevention of cardiovascular
disease. Cochrane Database Syst Rev 2013:Cd004816.
88. Third Report of the National Cholesterol Education Program (NCEP)
Expert Panel on Detection, Evaluation, and Treatment of High
Blood Cholesterol in Adults (Adult Treatment Panel III) Ô¨Ånal report.
Circulation 2002;106:3143-421.
89. van den Bogaard B, van den Born BJ, Fayyad R, Waters DD,
DeMicco DA, LaRosa JC, et al. On-treatment lipoprotein components and risk of cerebrovascular events in the Treating to New
Targets study. Eur J Clin Invest 2011;41:134-42.
90. McGirt MJ, Perler BA, Brooke BS, Woodworth GF, Coon A, Jain S,
et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors reduce the risk of perioperative stroke and mortality
after carotid endarterectomy. J Vasc Surg 2005;42:829-36; discussion: 836-7.
91. Kennedy J, Qu